N04BC09

92206-54-7

neupro

rotigotine hydrochloride

n-0923

Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson s disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. Like other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. Rotigotine was developed by Aderis Pharmaceuticals. In 1998, Aderis licensed worldwide development and commercialization rights for rotigotine to the German pharmaceutical company Schwarz Pharma (today a subsidiary of the Belgian company UCB S.A.). The drug has been approved by the EMEA for use in Europe in 2006 and is today being sold in several European countries. In 2007, the Neupro patch was approved by the Food and Drug Administration (FDA) as the first transdermal treatment of Parkinson s disease in the United States. However, as of 2008, Schwarz Pharma has recalled all Neupro patches in the United States and some in Europe because of problems with the delivery mechanism. Rotigotine has been authorized as a treatment for RLS since August 2008.

InChI=1S/C19H25NOS/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21/h3-7,13,16,21H,2,8-12,14H2,1H3

InChIKey=KFQYTPMOWPVWEJ-UHFFFAOYSA-N

rotigotine

obo2:dinto_DB05271

rotigotine

CCCN(CCC1=CC=CS1)C1CCC2=C(C1)C=CC=C2O

6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol

C19H25NOS

ChemSpider:51867

RxList:http://www.rxlist.com/neupro-drug.htm

IUPHAR:941

Guide To Pharmacology:941

BindingDB:50054062

National Drug Code Directory:50474-801-03

PubChem Substance:99443232

Drugs.com:http://www.drugs.com/cons/rotigotine-transdermal.html

Wikipedia:http://en.wikipedia.org/wiki/Rotigotine

PharmGKB:PA165958352

PubChem Compound:57537